Largest Published Study of Molecular Residual Disease in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions 02 February
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 29 January
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer 22 January
